Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 1/20 | 0.52 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | JAK2 | O60674 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.41 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4763766 | 0.76 | NPC1 (0.55) | KDM4ELMNAALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL25904148 | 0.75 | PDE3B (0.50) | PDE3BPDE3AKDM4ELMNAALDH1A1 | |
| SCHEMBL3280962 | 0.72 | AURKA (0.48) | KDM4ELMNAALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL4763954 | 0.72 | NPC1 (0.58) | KDM4ELMNAALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL25903697 | 0.71 | PDE3B (0.56) | PDE3BPDE3AKDM4ELMNAALDH1A1 | |
| SCHEMBL25904140 | 0.70 | PRKAB2 (0.50) | PDE3BPDE3AKDM4ELMNAALDH1A1 | |
| SCHEMBL1082799 | 0.70 | MAPT (0.56) | PDE3BPDE3AKDM4ELMNAALDH1A1 | |
| SCHEMBL4772556 | 0.70 | NPC1 (0.47) | KDM4ELMNAALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL25904127 | 0.69 | PDE3B (0.50) | PDE3BPDE3AKDM4ELMNAALDH1A1 | |
| SCHEMBL10378883 | 0.69 | PDE3B (1.00) | PDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7705151-B2 | 1,6 Naphthridines useful as inhibitors of SYK kinase | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2010-04-27 | — | — | US | disclosed |
| US-7705151-B2 | 1,6 Naphthridines useful as inhibitors of SYK kinase | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2010-04-27 | — | — | US | disclosed |
| US-7705151-B2 | 1,6 Naphthridines useful as inhibitors of SYK kinase | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2010-04-27 | — | — | US | disclosed |
| US-7678911-B2 | 1,6 naphthyridines useful as inhibitors of SYK kinase | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2010-03-16 | — | — | US | disclosed |
| US-7678911-B2 | 1,6 naphthyridines useful as inhibitors of SYK kinase | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2010-03-16 | — | — | US | disclosed |
| US-7678911-B2 | 1,6 naphthyridines useful as inhibitors of SYK kinase | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2010-03-16 | — | — | US | disclosed |
| US-20090171089-A1 | 1,6 NAPHTHRIDINES USEFUL AS INHIBITORS OF SYK KINASE | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-07-02 | — | — | US | disclosed |
| US-20090171089-A1 | 1,6 NAPHTHRIDINES USEFUL AS INHIBITORS OF SYK KINASE | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-07-02 | — | — | US | disclosed |
| US-20090171089-A1 | 1,6 NAPHTHRIDINES USEFUL AS INHIBITORS OF SYK KINASE | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-07-02 | — | — | US | disclosed |
| US-20080114024-A1 | 1,6 NAPHTHYRIDINES USEFUL AS INHIBITORS OF SYK KINASE | CYWIN CHARLES L | 2008-05-15 | — | — | US | disclosed |
| US-20080114024-A1 | 1,6 NAPHTHYRIDINES USEFUL AS INHIBITORS OF SYK KINASE | CYWIN CHARLES L | 2008-05-15 | — | — | US | disclosed |
| US-20080114024-A1 | 1,6 NAPHTHYRIDINES USEFUL AS INHIBITORS OF SYK KINASE | CYWIN CHARLES L | 2008-05-15 | — | — | US | disclosed |
| US-7321041-B2 | 1,6 Naphthyridines useful as inhibitors of SYK kinase | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2008-01-22 | — | — | US | disclosed |
| US-7321041-B2 | 1,6 Naphthyridines useful as inhibitors of SYK kinase | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2008-01-22 | — | — | US | disclosed |
| US-20030229090-A1 | 1,6 Naphthyridines useful as inhibitors of SYK kinase | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-12-11 | — | — | US | disclosed |
| US-20030158195-A1 | 1,6 naphthyridines useful as inhibitors of SYK kinase | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-08-21 | — | — | US | disclosed |
| WO-2003057695-A1 | 1,6 NAPHTHYRIDINES USEFUL AS INHIBITORS OF SYK KINASE | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229090-A1 | 1,6 Naphthyridines useful as inhibitors of SYK kinase | SYK, IRAK1, BTK | PDE3B 1316/4885PDE3A 1444/4885KDM4E 1930/4885 |
| US-20080114024-A1 | 1,6 NAPHTHYRIDINES USEFUL AS INHIBITORS OF SYK KINASE | SYK, IRAK1, IRAK3 | PDE3B 730/4885PDE3A 939/4885KDM4E 1585/4885 |
| US-20090171089-A1 | 1,6 NAPHTHRIDINES USEFUL AS INHIBITORS OF SYK KINASE | SYK, IRAK1, IRAK3 | PDE3B 1035/4885PDE3A 1208/4885KDM4E 1799/4885 |
| US-20030158195-A1 | 1,6 naphthyridines useful as inhibitors of SYK kinase | SYK, IRAK1, BTK | PDE3B 1316/4885PDE3A 1444/4885KDM4E 1930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.